Literature DB >> 17150020

Synthetic antibodies as therapeutics.

Germaine Fuh1.   

Abstract

Synthetic antibody libraries, whose repertoires are designed, have advanced in the last decade to rival natural repertoire-based libraries. Many types of diversity design have been shown to generate highly functional libraries. Defined template and defined diversity in synthetic antibody libraries improve the process of discovering and optimizing new antibodies. Synthetic libraries with different diversity design have targeted different epitopes on antigens, including epitopes that are unlikely to be targeted by immunization and hybridoma. Cross-species binding antibodies are prime examples of products generated by synthetic antibody libraries, and they are becoming the tools of choice to validate the selection of targeted molecules in therapeutic development. Synthetic antibody libraries complement the existing natural repertoire-based antibody libraries and hybridoma approach to maximize the potentials of antibodies as therapeutics.

Mesh:

Substances:

Year:  2007        PMID: 17150020     DOI: 10.1517/14712598.7.1.73

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  6 in total

1.  Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.

Authors:  Rolando Paciello; Richard A Urbanowicz; Gennaro Riccio; Emanuele Sasso; C Patrick McClure; Nicola Zambrano; Jonathan K Ball; Riccardo Cortese; Alfredo Nicosia; Claudia De Lorenzo
Journal:  J Gen Virol       Date:  2015-10-29       Impact factor: 3.891

2.  Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library.

Authors:  Dmitri Dormeshkin; Michail Shapira; Simon Dubovik; Anton Kavaleuski; Mikalai Katsin; Alexandr Migas; Alexander Meleshko; Sergei Semyonov
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

3.  Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

Authors:  Edward Htun van der Horst; Lawrence Chinn; Min Wang; Timothy Velilla; Hoang Tran; Yarrow Madrona; Andrew Lam; May Ji; Timothy C Hoey; Aaron K Sato
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

4.  Broad epitope coverage of a human in vitro antibody library.

Authors:  Arvind Sivasubramanian; Patricia Estep; Heather Lynaugh; Yao Yu; Adam Miles; Josh Eckman; Kevin Schutz; Crystal Piffath; Nadthakarn Boland; Rebecca Hurley Niles; Stéphanie Durand; Todd Boland; Maximiliano Vásquez; Yingda Xu; Yasmina Abdiche
Journal:  MAbs       Date:  2016-10-17       Impact factor: 5.857

Review 5.  Hybridoma technology: is it still useful?

Authors:  Jane Zveiter Moraes; Bárbara Hamaguchi; Camila Braggion; Enzo Reina Speciale; Fernanda Beatriz Viana Cesar; Gabriela de Fátima da Silva Soares; Juliana Harumi Osaki; Tauane Mathias Pereira; Rodrigo Barbosa Aguiar
Journal:  Curr Res Immunol       Date:  2021-03-22

6.  Differential screening of phage-ab libraries by oligonucleotide microarray technology.

Authors:  Paolo Monaci; Alessandra Luzzago; Claudia Santini; Alessandra De Pra; Mirko Arcuri; Francesca Magistri; Alessandro Bellini; Helenia Ansuini; Maria Ambrosio; Virginia Ammendola; Maria Giulia Bigotti; Agostino Cirillo; Maurizio Nuzzo; Annamaria Assunta Nasti; Philippe Neuner; Laura Orsatti; Monica Pezzanera; Andrea Sbardellati; Giuseppe Silvestre; Paolo Uva; Valentina Viti; Gaetano Barbato; Stefano Colloca; Anna Demartis; Emanuele De Rinaldis; Saverio Giampaoli; Armin Lahm; Fabio Palombo; Fabio Talamo; Alessandra Vitelli; Alfredo Nicosia; Riccardo Cortese
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.